Cargando…

Impaired interferon signature in severe COVID-19

Detalles Bibliográficos
Autor principal:	Gruber, Conor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	In Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192056/ https://www.ncbi.nlm.nih.gov/pubmed/32355328 http://dx.doi.org/10.1038/s41577-020-0335-0

Ejemplares similares

Comparative Upper Respiratory Tract Transcriptomic Profiling Reveals a Potential Role of Early Activation of Interferon Pathway in Severe COVID-19
por: Bhat, Shabir A., et al.
Publicado: (2022)

Dexamethasone restrains neutrophils in severe COVID-19
por: Flemming, Alexandra
Publicado: (2021)

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
por: Hadjadj, Jérôme, et al.
Publicado: (2020)

ACE2 is not induced by interferon
por: Saffern, Miriam
Publicado: (2020)

Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response
por: Fang, Terry C., et al.
Publicado: (2012)

Dysregulated early transcriptional signatures linked to mast cell and interferon responses are implicated in COVID-19 severity
por: MacCann, Rachel, et al.
Publicado: (2023)

Poor nasal immunity can lead to severe COVID-19
por: Flemming, Alexandra
Publicado: (2021)

Type I and type III interferon in opposition?
por: Park, Matthew D.
Publicado: (2020)

Do rogue antibodies make the difference between mild versus severe COVID-19?
por: Flemming, Alexandra
Publicado: (2021)

Cognitive Impairment 13 Months After Hospitalization for COVID-19
por: Stavem, Knut, et al.
Publicado: (2022)

Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
por: Aghemo, Alessio, et al.
Publicado: (2011)

Dysregulated Interferon Response Underlying Severe COVID-19
por: Lopez, LeAnn, et al.
Publicado: (2020)

COVID-19 infection in infant with severe CHD
por: Pexton, Natalie, et al.
Publicado: (2021)

INTERFERON AND CELL DIVISION : III. Effect of Interferon on the Division Cycle of L1210 Cells In Vitro
por: Macieira-Coelho, A., et al.
Publicado: (1971)

Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease
por: Madany, Emaan, et al.
Publicado: (2021)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?
por: Bahadoram, Mohammad, et al.
Publicado: (2021)

Suppression of local type I interferon by gut microbiota–derived butyrate impairs antitumor effects of ionizing radiation
por: Yang, Kaiting, et al.
Publicado: (2021)

Congenital heart disease and risk of severe COVID
por: Lim, Gregory B.
Publicado: (2021)

Type I Interferon Signature in Chilblain-Like Lesions Associated with the COVID-19 Pandemic
por: Aschoff, Roland, et al.
Publicado: (2020)

Characterisation of the pro-inflammatory cytokine signature in severe COVID-19
por: Hawerkamp, Heike C., et al.
Publicado: (2023)

The impact of COVID-19 related school shutdown on sleep in adolescents: a natural experiment
por: Gruber, Reut, et al.
Publicado: (2020)

Objective Olfactory Findings in Hospitalized Severe COVID-19 Patients
por: Lechien, Jerome R., et al.
Publicado: (2020)

Neopterin Predicts Disease Severity in Hospitalized Patients With COVID-19
por: Bellmann-Weiler, Rosa, et al.
Publicado: (2020)

A brief-review of the risk factors for covid-19 severity
por: Rod, J.E., et al.
Publicado: (2020)

Direct oral anticoagulant use and risk of severe COVID‐19
por: Flam, B., et al.
Publicado: (2020)

Diaphragm dysfunction in severe COVID‐19 as determined by neuromuscular ultrasound
por: Farr, Ellen, et al.
Publicado: (2021)

Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19
por: Fetters, Kirk B., et al.
Publicado: (2022)

T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers
por: Seraceni, Silva, et al.
Publicado: (2022)

Dampened STING-Dependent Interferon Activation in Bats
por: Xie, Jiazheng, et al.
Publicado: (2018)

Molecular signatures in the progression of COVID-19 severity
por: De, Ronika, et al.
Publicado: (2022)

Estimating the efficacy of symptom-based screening for COVID-19
por: Callahan, Alison, et al.
Publicado: (2020)

Pulmonary vascular proliferation in patients with severe COVID-19: an autopsy study
por: Pérez-Mies, Belén, et al.
Publicado: (2021)

Acute appendicitis severity during the early COVID-19 pandemic period
por: Zaikos, Thomas D, et al.
Publicado: (2021)

ADAMTS13 regulation of VWF multimer distribution in severe COVID‐19
por: Ward, Soracha E., et al.
Publicado: (2021)

Circulating Calprotectin as a Predictive and Severity Biomarker in Patients with COVID-19
por: Norman, Gary L., et al.
Publicado: (2022)

Impact of vaccination and the omicron variant on COVID-19 severity in pregnant women
por: Kim, Haemin, et al.
Publicado: (2023)

Association Between Bariatric Surgery and Severe COVID-19 Outcomes in Florida
por: Chen, Guanming, et al.
Publicado: (2022)

Lack of vitamin D predicts impaired long-term immune response to COVID-19 vaccination
por: di Filippo, Luigi, et al.
Publicado: (2023)

Uncoupling interferons and the interferon signature explain clinical and transcriptional subsets in SLE
por: Gómez-Bañuelos, Eduardo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f124att8kbrkch0ln2nnfo2qve